相似文献
1
Chronic Obstructive Pulmonary Disease Phenotypes: Implications for Care.
Mayo Clin Proc. 2017 Jul;92(7):1104-1112. doi: 10.1016/j.mayocp.2017.03.020.
2
Phenotypes of chronic obstructive pulmonary disease.
COPD. 2007 Dec;4(4):355-84. doi: 10.1080/15412550701629663.
3
Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Dec;164(4):325-356. doi: 10.5507/bp.2020.056.
4
Geographic variations of the prevalence and distribution of COPD phenotypes in Spain: "the ESPIRAL-ES study".
Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1115-1124. doi: 10.2147/COPD.S158031. eCollection 2018.
5
Evaluation Of Polymorphisms And Their Relationship With Chronic Obstructive Pulmonary Disease Phenotypes.
Int J Chron Obstruct Pulmon Dis. 2019 Oct 3;14:2267-2272. doi: 10.2147/COPD.S213519. eCollection 2019.
6
Clinical outcomes of chronic obstructive pulmonary disease phenotypes. One center prospective study.
Adv Respir Med. 2021;89(4):369-377. doi: 10.5603/ARM.a2021.0086.
7
Phenotyping Before Starting Treatment in COPD?
COPD. 2017 Jun;14(3):367-374. doi: 10.1080/15412555.2017.1303041. Epub 2017 Apr 7.
8
Computed tomography phenotypes in severe, early-onset chronic obstructive pulmonary disease.
COPD. 2007 Dec;4(4):331-7. doi: 10.1080/15412550701601274.
9
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
Arch Bronconeumol. 2012 Mar;48(3):86-98. doi: 10.1016/j.arbres.2011.10.007. Epub 2011 Dec 22.
10
[PERSONALIZED MEDICINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT].
Rev Med Liege. 2015 May-Jun;70(5-6):310-5.
引用本文的文献
1
The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and preserved ratio impaired spirometry: NHANES 2007-2012.
Lipids Health Dis. 2025 Apr 25;24(1):157. doi: 10.1186/s12944-025-02571-0.
2
GOLD grade-specific characterization of COPD in the COSYCONET multi-center trial: comparison of semiquantitative MRI and quantitative CT.
Eur Radiol. 2025 Jan 8. doi: 10.1007/s00330-024-11269-3.
3
The Intriguing Connection Between the Gut and Lung Microbiomes.
Pathogens. 2024 Nov 15;13(11):1005. doi: 10.3390/pathogens13111005.
4
Factors Affecting Survival in Severe and Very Severe COPD after Admission in ICUs of Tertiary Care Centers of India (FAST COPD): Study Protocol for a Multicentric Cohort Study.
Indian J Crit Care Med. 2024 Jun;28(6):552-560. doi: 10.5005/jp-journals-10071-24728.
5
Reduced Tolerogenic Program Death-Ligand 1-Expressing Conventional Type 1 Dendritic Cells Are Associated with Rapid Decline in Chronic Obstructive Pulmonary Disease.
Cells. 2024 May 20;13(10):878. doi: 10.3390/cells13100878.
6
Frailty and its influence on mortality and morbidity in COPD: A Systematic Review and Meta-Analysis.
Intern Emerg Med. 2023 Nov;18(8):2423-2434. doi: 10.1007/s11739-023-03405-6. Epub 2023 Sep 5.
7
Three-Month Variability of Commonly Evaluated Biomarkers in Clinically Stable COPD.
Int J Chron Obstruct Pulmon Dis. 2023 Jul 18;18:1475-1486. doi: 10.2147/COPD.S396549. eCollection 2023.
8
Respiratory Care Management of COPD Exacerbations.
Respir Care. 2023 Jun;68(6):821-837. doi: 10.4187/respcare.11069.
9
The gut microbiome is a significant risk factor for future chronic lung disease.
J Allergy Clin Immunol. 2023 Apr;151(4):943-952. doi: 10.1016/j.jaci.2022.12.810. Epub 2022 Dec 29.
10
Chronic moderate hypercapnia suppresses ventilatory responses to acute CO<sub>2</sub> challenges.
J Appl Physiol (1985). 2022 Nov 1;133(5):1106-1118. doi: 10.1152/japplphysiol.00407.2022. Epub 2022 Sep 22.
本文引用的文献
1
The impact of coping on the somatic and mental status of patients with COPD: a cross-sectional study.
Int J Chron Obstruct Pulmon Dis. 2016 Jun 20;11:1343-51. doi: 10.2147/COPD.S106765. eCollection 2016.
2
Physical frailty and pulmonary rehabilitation in COPD: a prospective cohort study.
Thorax. 2016 Nov;71(11):988-995. doi: 10.1136/thoraxjnl-2016-208460. Epub 2016 Jun 12.
3
Analysis of Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Defined on the Basis of Bronchodilator Response and Degree of Emphysema.
Ann Am Thorac Soc. 2016 Sep;13(9):1483-9. doi: 10.1513/AnnalsATS.201511-761OC.
4
Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis.
Lancet Respir Med. 2016 Jun;4(6):454-62. doi: 10.1016/S2213-2600(16)00098-9. Epub 2016 Apr 6.
5
Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States.
Ann Am Thorac Soc. 2016 Jun;13(6):803-10. doi: 10.1513/AnnalsATS.201508-554OC.
6
Roflumilast: a review of its use in the treatment of COPD.
Int J Chron Obstruct Pulmon Dis. 2016 Jan 6;11:81-90. doi: 10.2147/COPD.S89849. eCollection 2016.
7
Asthma and chronic obstructive pulmonary disease overlap syndrome (ACOS): structured literature review and physician insights.
Expert Rev Respir Med. 2016;10(3):363-71. doi: 10.1586/17476348.2016.1144476. Epub 2016 Feb 15.
8
Self-management and quality of life in chronic obstructive pulmonary disease (COPD): The mediating effects of positive affect.
Patient Educ Couns. 2016 Apr;99(4):617-623. doi: 10.1016/j.pec.2015.10.031. Epub 2015 Nov 10.
9
Forecasting COPD hospitalization in the clinic: optimizing the chronic respiratory questionnaire.
Int J Chron Obstruct Pulmon Dis. 2015 Oct 22;10:2295-301. doi: 10.2147/COPD.S87469. eCollection 2015.
10
Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis.
BMJ Open. 2015 Oct 26;5(10):e009183. doi: 10.1136/bmjopen-2015-009183.
Zotero 插件